This story originally ran on Nov. 18.
Covance and Rules Based Medicine today announced they have entered into a biomarker alliance and services agreement.
Under the terms of the deal, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, while RBM will use Covance as its exclusive referral source for laboratory-based tests.
Financial terms of the deal were not disclosed.
The agreement is the latest in a series of moves during the past year by Covance to build up its biomarker services business. In December, Covance acquired a minority stake in Caprion Proteomics. In return, it became the exclusive contract research organization distributor for Caprion's proteomic biomarker services [See PM 12/18/08]. It also has established a Biomarker Center of Excellence, and in the summer bought Merck's gene expression laboratory in Seattle.
The agreement with RBM "strengthens our ability to provide comprehensive biomarker discovery, verification, validation, and deployment in both the preclinical and clinical setting," Deborah Tanning, corporate senior vice president and president of Covance Central Laboratory Services, said in a statement.
Covance, a CRO based in Princeton, NJ, focuses on drug development services. RBM, headquartered in Austin, Texas, is a CLIA-certified biomarker testing laboratory.